

Clara Balsano, PhD
Wan-Long Chuang, MD, PhD
Editors-in-Chief of *World Journal of Hepatology*

May 23rd 2016

Dear Editors,

Please find enclosed the revised version of our editorial (Manuscript NO.: 25566) entitled "**Sofosbuvir/velpatasvir: a promising combination**" by Drs. Bonaventura and myself for re-consideration for publication in *World Journal of Hepatology*.

We performed all changes suggested by the reviewers. We hope that this revised version of our manuscript will be reconsidered and deemed as suitable for publication in *World Journal of Hepatology*. We are indebted with the reviewers for their careful reading and pertinent comments, which improved our manuscript. Changes from the first version were written as underlined in this revised version.

All authors have read and approved the submission of the manuscript and declared that no conflict of interest exists.

My address, telephone number, Fax number and e-mail address are on the bottom of this letter. The material submitted for publication has not been previously reported and is not under consideration for publication elsewhere. I will serve as the corresponding author of this manuscript.

Specific points:

Reviewer #1

- Comment: "This Editorial paper titled "Advances in HCV treatment: the promised land" is very interesting to publish in WJG as an editorial paper. Although this editorial paper is interesting, if there is one figure, which shows HCV construct and where are part anti-HCV drugs inhibit." .

Reply: We thank the reviewer for his/her suggestion. We have prepared a figure containing both a simplified overview of HCV structure and targets of direct antiviral agents.

Reviewer #2

- Comment: "Major criticism This manuscript is a report of trials and lacks of clinical message. Minor criticisms The title does not reflect the treated subject. A reader, on the basis of the title, can imagine an extensive review, not limited to the combination SOFOSBUVIR AND VELPATASVIR."

Reply: The editorial was intentionally focused on a single trial in order to express a personal comment and contained also a small, clinical message in terms of efficacy and safety ("...In the ASTRAL-2 trial, patients who had received SOF/VEL met the primary endpoint with no virologic failures. In the ASTRAL-3 trial, patients who were administered with SOF/VEL gained a SVR, but 4% of them showed virologic failure after the end of treatment. Overall, the rate of SVR was higher among patients without cirrhosis and who did not receive any previous treatment...."). Besides, the part on the safety of the association sofosbuvir/velpatasvir was enlarged (pages 6-7).